Company
LON:STX
Shield Therapeutics PLC is a commercial-stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer ® /Feraccru ® (ferric maltol). The group has launched Accrufer® in the US and Feraccru ® is commercialized in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical for the development and commercialization of Accrufer ® / Feraccru ® in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co in the Republic of Korea, and with KYE Pharmaceuticals in Canada.
175 stories · page 4 of 9
"Based on all our collective insights, we are even more confident today about Accrufer becoming the oral iron of choice," said Greg Madison, the chief executive officer of Shield Therapeutics.
Marketing approval for Shield-developed Accrufer is expected in the first half of next year
America is the key thrust for the group as it looks to roll out its ferric maltol product
Shield will receive up to £1mln in upfront, development and sales milestones
Accrufer placed on formulary 1, a continually updated list of prescription drugs approved for reimbursement in the US
In Europe, the drug is branded as Ferracru and marketed by partner Norgine
Dr. Menoyo's expertise in establishing and executing medical affairs strategies "will be extremely valuable to Shield for the launch of Accrufer in the US,” said CEO Greg Madison
During the first quarter, the group changed tack in the US, shifting away from its out-licensing model to launch Accrufer off its own bat in the US
Under the deal with Korea Pharma Co Ltd, the company said it will receive an upfront payment of £0.5mln as well as £1.5mln upon first commercial sale and up to £4mln in milestone payments
Investigators assessed the potential of Feraccru (known as Accrufer in the US, and also called ferric maltol)
The iron deficiency product will be available to doctors and other prescribers in all parts of the US
Greg Madison will take over on June 1 from Tim Watts, who will remain as an executive director until September 30
Preparatory work on the launch has accelerated dramatically in the last couple of months
The company’s focus is on addressing iron deficiency with its lead product Feraccru/Accrufer (ferric maltol)
A glance at some of the day's highlights from the Proactive Investors newswire
Chief executive Tim Watts said: "With the upcoming launch of Accrufer in the US I believe that Shield will be of increasing relevance to US-based investors"
They are Fabiana Lacerca-Allen and Anders Lundstrom
Increasing sales in the US are estimated to turn the monthly cash flow positive between 15-18 months after launch
Ferric maltol was used in patients with both IBD and iron-deficiency anaemia
Archive
Samarkand Group Limited (AQSE:SMK), the cross-border eCommerce technology and retail group opening up the world's largest market for brands and retailers, has joined the Apex Segment of the Aquis Stock Exchange Growth Market. Raised £17m at
